Literature DB >> 31768341

A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2019        PMID： 31768341      PMCID： PMC6872999          DOI： 10.1159/000502905

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  43 in total

1.  Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Yohei Koizumi; Yoichi Hiasa; Kazuto Tajiri; Hidenori Toyoda; Toshifumi Tada; Hironori Ochi; Koji Joko; Noritomo Shimada; Akihiro Deguchi; Toru Ishikawa; Michitaka Imai; Kunihiko Tsuji; Kojiro Michitaka
Journal:  Dig Dis       Date:  2017-10-17       Impact factor: 2.404

2.  Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.

Authors:  Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
Journal:  Dig Dis       Date:  2017-10-17       Impact factor: 2.404

3.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

4.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

Review 5.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

8.  Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.

Authors:  Sadahisa Ogasawara; Tetsuhiro Chiba; Yoshihiko Ooka; Naoya Kanogawa; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Fumihiko Kanai; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  Oncology       Date:  2014-09-06       Impact factor: 2.935

9.  Pathology of small hepatocellular carcinoma. A proposal for a new gross classification.

Authors:  T Kanai; S Hirohashi; M P Upton; M Noguchi; K Kishi; M Makuuchi; S Yamasaki; H Hasegawa; K Takayasu; N Moriyama
Journal:  Cancer       Date:  1987-08-15       Impact factor: 6.860

10.  Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.

Authors:  Mitsunobu R Kano; Yukari Komuta; Caname Iwata; Masako Oka; Yo-taro Shirai; Yasuyuki Morishita; Yasuyoshi Ouchi; Kazunori Kataoka; Kohei Miyazono
Journal:  Cancer Sci       Date:  2008-11-24       Impact factor: 6.518
View more
  40 in total

1.  A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

Authors:  Masatoshi Kudo; Kwang-Hyub Han; Sheng-Long Ye; Jian Zhou; Yi-Hsiang Huang; Shi-Ming Lin; Chung-Kwe Wang; Masafumi Ikeda; Stephen Lam Chan; Su Pin Choo; Shiro Miyayama; Ann Lii Cheng
Journal:  Liver Cancer       Date:  2020-05-13       Impact factor: 11.740

2.  A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-03-05       Impact factor: 11.740

Review 3.  Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2020-11-17       Impact factor: 11.740

4.  Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.

Authors:  Keisuke Koroki; Sadahisa Ogasawara; Yoshihiko Ooka; Hiroaki Kanzaki; Kengo Kanayama; Susumu Maruta; Takahiro Maeda; Masayuki Yokoyama; Toru Wakamatsu; Masanori Inoue; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Eiichiro Suzuki; Shingo Nakamoto; Shin Yasui; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Satoshi Kuboki; Masayuki Ohtsuka; Masaru Miyazaki; Osamu Yokosuka; Naoya Kato
Journal:  Liver Cancer       Date:  2020-07-22       Impact factor: 11.740

5.  Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).

Authors:  Masatoshi Kudo; Richard S Finn; Manabu Morimoto; Kun-Ming Rau; Masafumi Ikeda; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Bruno Daniele; Ho Yeong Lim; David W McIlwain; Reigetsu Yoshikawa; Kenichi Nakamura; Kun Liang; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X Zhu
Journal:  Liver Cancer       Date:  2021-07-12       Impact factor: 11.740

6.  New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy.

Authors:  Anil C Anand; Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2021-04-27

7.  Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.

Authors:  Yusuke Kawamura; Masahiro Kobayashi; Junichi Shindoh; Yuta Kobayashi; Satoshi Okubo; Licht Tominaga; Akira Kajiwara; Kayoko Kasuya; Soichi Iritani; Shunichiro Fujiyama; Tetsuya Hosaka; Satoshi Saitoh; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Kenji Ikeda; Yasuji Arase; Masaji Hashimoto; Tokuyo Kozuka; Hiromitsu Kumada
Journal:  Liver Cancer       Date:  2020-10-30       Impact factor: 11.740

8.  Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma.

Authors:  Mingyu Chen; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Jian Lin; Chenhao Tong; Jiliang Shen; Bin Zhang; Jennifer Wu; Christine Pocha; Masatoshi Kudo; Amedeo Amedei; Franco Trevisani; Pil Soo Sung; Victor M Zaydfudim; Tatsuo Kanda; Xiujun Cai
Journal:  Liver Cancer       Date:  2021-01-07       Impact factor: 11.740

9.  Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria.

Authors:  Ya-Wen Hung; I-Cheng Lee; Chen-Ta Chi; Rheun-Chuan Lee; Chien-An Liu; Nai-Chi Chiu; Hsuen-En Hwang; Yee Chao; Ming-Chih Hou; Yi-Hsiang Huang
Journal:  Liver Cancer       Date:  2021-07-22       Impact factor: 11.740

10.  A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-10-12       Impact factor: 11.740
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.